These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 19110596

  • 1. Mechanisms of stimulation of granulocytopoiesis with neupogen in patients with breast cancer during chemotherapy.
    Khrichkova TY, Gol'dberg VE, Zhdanov VV, Matyash MG, Vysotckaya VV, Simolina EI, Shatalova VA, Popova NO, Miroshnichenko LA, Dygai AM.
    Bull Exp Biol Med; 2008 Apr; 145(4):467-71. PubMed ID: 19110596
    [Abstract] [Full Text] [Related]

  • 2. Mechanisms of Granulocytopoiesis Recovery Stimulation with Filgrastim in Breast Cancer Patients Receiving Chemotherapy.
    Goldberg VE, Polyakova TY, Popova NO, Vysotskaya VV, Simolina EI, Dudnikova EA, Goncharova NM, Belevich YV, Tuzikova TP, Goldberg AV, Miroshnichenko LA, Udut EV, Simanina EV, Zyuz'kov GN, Zhdanov VV, Dygai AM.
    Bull Exp Biol Med; 2018 Nov; 166(1):63-68. PubMed ID: 30450524
    [Abstract] [Full Text] [Related]

  • 3. Mechanisms of granulocytopoiesis-stimulating activity of immobilized granulocytic colony-stimulating factor in cytostatic myelosuppression.
    Dygai AM, Vereshchagin EI, Zhdanov VV, Zyuz'kov GN, Ermakova NN, Madonov PG, Miroshnichenko LA, Minakova MY, Simanina EV, Stavrova LA, Udut EV, Firsova TV, Khrichkova TY.
    Bull Exp Biol Med; 2009 Jul; 148(1):49-53. PubMed ID: 19902095
    [Abstract] [Full Text] [Related]

  • 4. Reactions of granulocytic lineage of hemopoiesis and mechanisms of their development in combined treatment with adriablastin and taxotere.
    Gol'dberg VE, Khrichkova TY, Shatalova VA, Popova NO, Burshtein ES, Minakova MY, Zhdanov VV, Dygai AM.
    Bull Exp Biol Med; 2011 Apr; 150(6):718-24. PubMed ID: 22235426
    [Abstract] [Full Text] [Related]

  • 5. XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy.
    del Giglio A, Eniu A, Ganea-Motan D, Topuzov E, Lubenau H.
    BMC Cancer; 2008 Nov 12; 8():332. PubMed ID: 19014494
    [Abstract] [Full Text] [Related]

  • 6. Use of doxorubicin plus cyclophosphamide followed by docetaxel as adjuvant chemotherapy for breast cancer.
    Livi L, Meattini I, de Luca Cardillo C, Scotti V, Agresti B, Franzese C, Sanchez L, Nori J, Bertocci S, Cassani S, Bianchi S, Cataliotti L, Biti G.
    J Chemother; 2011 Feb 12; 23(1):36-9. PubMed ID: 21482493
    [Abstract] [Full Text] [Related]

  • 7. Responses of Blood System to Doxorubicin/Docetaxel Chemotherapy in Patients with Breast Cancer.
    Goldberg VE, Polyakova TY, Popova NO, Vysotskaya VV, Simolina EI, Dudnikova EA, Goncharova NM, Belevich YV, Grigor'ev EG, Goldberg AV, Dygai AM.
    Bull Exp Biol Med; 2019 Dec 12; 168(2):275-279. PubMed ID: 31782001
    [Abstract] [Full Text] [Related]

  • 8. Development of a new G-CSF product based on biosimilarity assessment.
    Gascon P, Fuhr U, Sörgel F, Kinzig-Schippers M, Makhson A, Balser S, Einmahl S, Muenzberg M.
    Ann Oncol; 2010 Jul 12; 21(7):1419-1429. PubMed ID: 20019087
    [Abstract] [Full Text] [Related]

  • 9. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
    Nabholtz JM, Cantin J, Chang J, Guevin R, Patel R, Tkaczuk K, Vodvarka P, Lindsay MA, Reese D, Riva A, Mackey J.
    Clin Breast Cancer; 2002 Oct 12; 3(4):268-75. PubMed ID: 12425755
    [Abstract] [Full Text] [Related]

  • 10. Role of hemopoietic precursors of various classes in the effect of granulocyte colony-stimulating factor on hemopoiesis during cytostatic-induced myelosuppression.
    Dygai AM, Skurikhin EG, Pershina OV, Andreeva TV, Khmelevskaya ES, Minakova MJ.
    Bull Exp Biol Med; 2010 Oct 12; 149(4):416-20. PubMed ID: 21234432
    [Abstract] [Full Text] [Related]

  • 11. Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide.
    Ip EJ, Lee-Ma A, Troxell LS, Chan J.
    Am J Health Syst Pharm; 2008 Aug 15; 65(16):1552-5. PubMed ID: 18693211
    [Abstract] [Full Text] [Related]

  • 12. Effects of granulocyte colony-stimulating factor and hyaluronidase on the formation of blood system reactions.
    Goldberg ED, Dygai AM, Zyuz'kov GN, Zhdanov VV.
    Bull Exp Biol Med; 2008 Jun 15; 145(6):682-7. PubMed ID: 19110550
    [Abstract] [Full Text] [Related]

  • 13. Adjuvant docetaxel for node-negative breast cancer.
    Venniyoor A.
    N Engl J Med; 2011 Mar 10; 364(10):976-7; author reply 977-8. PubMed ID: 21388324
    [No Abstract] [Full Text] [Related]

  • 14. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
    Nabholtz JM, Smylie M, Mackey J, Paterson A, Noel D, al-Tweigeri, Janowska A, Delorme F, Riva A.
    Oncology (Williston Park); 1997 Jun 10; 11(6 Suppl 6):25-7. PubMed ID: 9213324
    [Abstract] [Full Text] [Related]

  • 15. Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies.
    Bondarenko IM, Bias P, Buchner A.
    Support Care Cancer; 2016 Jan 10; 24(1):267-273. PubMed ID: 26024743
    [Abstract] [Full Text] [Related]

  • 16. Effect of granulocytic colony-stimulating factor on cytostatic-suppressed granulocytopoiesis under conditions of exhausted catecholamine depot.
    Dygai AM, Skurikhin EG, Pershina OV, Simanina EV, Minakova MY, Ermakova NN, Firsova TV, Khmelevskay ES.
    Bull Exp Biol Med; 2009 May 10; 147(5):609-12. PubMed ID: 19907751
    [Abstract] [Full Text] [Related]

  • 17. Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.
    Gladkov OA, Buchner A, Bias P, Müller U, Elsässer R.
    Support Care Cancer; 2016 Jan 10; 24(1):395-400. PubMed ID: 26092233
    [Abstract] [Full Text] [Related]

  • 18. Prolonged neutropenia after dose-dense chemotherapy with pegfilgrastim.
    Ishiguro H, Kitano T, Yoshibayashi H, Toi M, Ueno T, Yasuda H, Yanagihara K, Garbo CL, Fukushima M.
    Ann Oncol; 2008 May 10; 19(5):1019; author reply 1019-20. PubMed ID: 18325914
    [No Abstract] [Full Text] [Related]

  • 19. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196.
    Sparano JA, O'Neill A, Schaefer PL, Falkson CI, Wood WC.
    J Clin Oncol; 2000 Jun 10; 18(12):2369-77. PubMed ID: 10856096
    [Abstract] [Full Text] [Related]

  • 20. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
    Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I, Neumann TA, Hill LR, Liang BC.
    J Clin Oncol; 2002 Feb 01; 20(3):727-31. PubMed ID: 11821454
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.